Marco Santoro currently works as a Researcher at the Hematology Unit of the University of Palermo. He received a Bachelor of Medicine in October 2012, the Hematology Specialization degree in September 2017 and was declared a Ph.D. in Experimental Oncology and Surgery in March 2021, with a thesis entitled “The antineoplastic role of STAT5 inhibition in BCRABL1-positive cells exposed to Pimozide alone and in combination with Dasatinib and Ponatinib”. Dr. Santoro’s main research field is Myeloproliferative Neoplasms, but he maintains an interest in many aspects of hematological oncology. He is the Principal Investigator of ongoing observational and experimental studies on myeloproliferative neoplasms at the Hematology Unit where he works.